S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Regenxbio News Headlines (NASDAQ:RGNX)

$38.35
-0.05 (-0.13 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$38.13
Now: $38.35
$39.44
50-Day Range
$31.84
MA: $36.83
$39.90
52-Week Range
$30.38
Now: $38.35
$73.81
Volume418,699 shs
Average Volume561,259 shs
Market Capitalization$1.41 billion
P/E Ratio16.11
Dividend YieldN/A
Beta0.82

Headlines

Regenxbio (NASDAQ RGNX) News Headlines

Source:
DateHeadline
Regenxbio Inc (NASDAQ:RGNX) Expected to Post Earnings of -$0.89 Per ShareRegenxbio Inc (NASDAQ:RGNX) Expected to Post Earnings of -$0.89 Per Share
www.americanbankingnews.com - October 22 at 7:24 PM
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress - PRNewswireREGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress - PRNewswire
www.prnewswire.com - October 17 at 5:19 PM
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress - Yahoo FinanceREGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress - Yahoo Finance
finance.yahoo.com - October 17 at 7:18 AM
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual CongressREGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress
finance.yahoo.com - October 17 at 7:18 AM
Analyzing Regenxbio (NASDAQ:RGNX) & Aevi Genomic Medicine (NASDAQ:GNMX)Analyzing Regenxbio (NASDAQ:RGNX) & Aevi Genomic Medicine (NASDAQ:GNMX)
www.americanbankingnews.com - October 16 at 1:12 AM
Regenxbio Inc (NASDAQ:RGNX) Short Interest UpdateRegenxbio Inc (NASDAQ:RGNX) Short Interest Update
www.americanbankingnews.com - October 16 at 12:50 AM
RegenxBio gets positive interim data for eye disease treatment - Washington Business JournalRegenxBio gets positive interim data for eye disease treatment - Washington Business Journal
www.bizjournals.com - October 15 at 5:57 PM
RegenxBio gets positive interim data for eye disease treatmentRegenxBio gets positive interim data for eye disease treatment
finance.yahoo.com - October 15 at 5:57 PM
Form 8-K REGENXBIO Inc. For: Oct 11 - StreetInsider.comForm 8-K REGENXBIO Inc. For: Oct 11 - StreetInsider.com
www.streetinsider.com - October 15 at 12:56 PM
Adverum and Regenxbio go opposite ways on wet AMD data - Seeking AlphaAdverum and Regenxbio go opposite ways on wet AMD data - Seeking Alpha
seekingalpha.com - October 14 at 6:19 PM
Regenxbio (RGNX) Reports Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for Treatment of Wet AMD - StreetInsider.comRegenxbio (RGNX) Reports Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for Treatment of Wet AMD - StreetInsider.com
www.streetinsider.com - October 14 at 8:19 AM
3 Beaten-Up Biotechs -- Are They Buys? - Motley Fool3 Beaten-Up Biotechs -- Are They Buys? - Motley Fool
www.fool.com - October 13 at 1:04 PM
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting - PRNewswireREGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting - PRNewswire
www.prnewswire.com - October 11 at 11:59 PM
Big Pharma Has Mad Love For These 2 Biotechs - Motley FoolBig Pharma Has Mad Love For These 2 Biotechs - Motley Fool
www.fool.com - October 11 at 6:58 PM
Morgan Stanley Trims Regenxbio (NASDAQ:RGNX) Target Price to $59.00Morgan Stanley Trims Regenxbio (NASDAQ:RGNX) Target Price to $59.00
www.americanbankingnews.com - October 11 at 2:01 PM
Wet AMD Space in Focus: New Drug Approvals & Key Advancements - NasdaqWet AMD Space in Focus: New Drug Approvals & Key Advancements - Nasdaq
www.nasdaq.com - October 10 at 12:15 PM
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita - Yahoo FinanceUltragenyx Gets FDA Approval for Label Expansion of Crysvita - Yahoo Finance
finance.yahoo.com - October 2 at 4:50 PM
$6.26 Million in Sales Expected for Regenxbio Inc (NASDAQ:RGNX) This Quarter$6.26 Million in Sales Expected for Regenxbio Inc (NASDAQ:RGNX) This Quarter
www.americanbankingnews.com - October 2 at 1:51 PM
REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference - PRNewswireREGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference - PRNewswire
www.prnewswire.com - September 30 at 5:40 PM
Regenxbio Inc (NASDAQ:RGNX) Expected to Post Earnings of -$0.50 Per ShareRegenxbio Inc (NASDAQ:RGNX) Expected to Post Earnings of -$0.50 Per Share
www.americanbankingnews.com - September 30 at 6:39 AM
Regenxbio Inc (NASDAQ:RGNX) Receives Consensus Recommendation of "Hold" from AnalystsRegenxbio Inc (NASDAQ:RGNX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 30 at 3:29 AM
Regenxbio And RGX-501 In Homozygous Familial Hypercholesterolemia - Seeking AlphaRegenxbio And RGX-501 In Homozygous Familial Hypercholesterolemia - Seeking Alpha
seekingalpha.com - September 20 at 8:45 AM
An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% UndervaluedAn Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued
finance.yahoo.com - September 20 at 8:45 AM
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8% - Yahoo FinanceREGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8% - Yahoo Finance
finance.yahoo.com - September 14 at 12:18 PM
This Rockville biotech has added another deal to its growth plan - Washington Business JournalThis Rockville biotech has added another deal to its growth plan - Washington Business Journal
www.bizjournals.com - September 10 at 11:44 AM
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 - Yahoo FinanceREGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 - Yahoo Finance
finance.yahoo.com - September 6 at 5:47 PM
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 - PRNewswireREGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 - PRNewswire
www.prnewswire.com - September 5 at 12:01 PM
Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With RegenxbioClearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbio
www.benzinga.com - September 4 at 11:13 AM
3 Top Biotech Stocks to Buy Right Now - Nasdaq3 Top Biotech Stocks to Buy Right Now - Nasdaq
www.nasdaq.com - August 29 at 11:22 AM
REGENXBIO to Present at Upcoming Investor Conferences - PRNewswireREGENXBIO to Present at Upcoming Investor Conferences - PRNewswire
www.prnewswire.com - August 29 at 11:22 AM
REGENXBIO to Present at Upcoming Investor ConferencesREGENXBIO to Present at Upcoming Investor Conferences
finance.yahoo.com - August 29 at 11:22 AM
REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October - Yahoo FinanceREGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October - Yahoo Finance
finance.yahoo.com - August 28 at 12:28 PM
REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October - PRNewswireREGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October - PRNewswire
www.prnewswire.com - August 27 at 7:06 PM
REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in OctoberREGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
finance.yahoo.com - August 27 at 9:36 AM
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares - Yahoo FinanceRegenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares - Yahoo Finance
finance.yahoo.com - August 22 at 12:14 PM
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of SharesRegenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares
finance.yahoo.com - August 21 at 8:04 PM
Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT - Yahoo FinanceEdited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT - Yahoo Finance
finance.yahoo.com - August 12 at 11:56 PM
Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q2 2019 Results - Earnings Call Transcript - Seeking AlphaRegenxbio, Inc. (RGNX) CEO Kenneth Mills on Q2 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 7:29 PM
Regenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript - Yahoo FinanceRegenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript - Yahoo Finance
finance.yahoo.com - August 9 at 7:29 PM
Regenxbio Inc. (RGNX) Q2 2019 Earnings Call TranscriptRegenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 9 at 7:29 PM
Form 8-K REGENXBIO Inc. For: Aug 07 - StreetInsider.comForm 8-K REGENXBIO Inc. For: Aug 07 - StreetInsider.com
www.streetinsider.com - August 9 at 12:28 AM
Regenxbio (RGNX) Tops Q2 EPS by 57c, Revenues Miss - StreetInsider.comRegenxbio (RGNX) Tops Q2 EPS by 57c, Revenues Miss - StreetInsider.com
www.streetinsider.com - August 9 at 12:28 AM
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo FinanceRegenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - August 8 at 7:26 PM
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD - PRNewswireREGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD - PRNewswire
www.prnewswire.com - August 8 at 7:26 PM
Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMTEdited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT
finance.yahoo.com - August 8 at 7:26 PM
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates - NasdaqRegenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq
www.nasdaq.com - August 8 at 5:01 AM
Is REGENXBIO Inc.s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers? - Yahoo FinanceIs REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers? - Yahoo Finance
finance.yahoo.com - August 7 at 7:23 PM
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD - Yahoo FinanceREGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD - Yahoo Finance
finance.yahoo.com - August 7 at 7:23 PM
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMDREGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
finance.yahoo.com - August 7 at 7:23 PM
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue EstimatesRegenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 7 at 7:23 PM
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel